Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles

The use of small molecule drugs in cancer chemotherapy has mostly been limited by dose-dependent toxicity and development of drug resistance resulting from repeated administrations. To overcome such problems, efforts have been made to develop drug delivery systems that can bear multiple therapeutic...

Full description

Bibliographic Details
Main Authors: Lee, A., Dhillon, S., Wang, Y., Pervaiz, Shazib, Yang, Y.
Format: Conference Paper
Published: American Chemical Society 2012
Online Access:https://www.acs.org/content/acs/en/meetings/nationalmeetings/programarchive.html
http://hdl.handle.net/20.500.11937/53417
_version_ 1848759139253092352
author Lee, A.
Dhillon, S.
Wang, Y.
Pervaiz, Shazib
Yang, Y.
author_facet Lee, A.
Dhillon, S.
Wang, Y.
Pervaiz, Shazib
Yang, Y.
author_sort Lee, A.
building Curtin Institutional Repository
collection Online Access
description The use of small molecule drugs in cancer chemotherapy has mostly been limited by dose-dependent toxicity and development of drug resistance resulting from repeated administrations. To overcome such problems, efforts have been made to develop drug delivery systems that can bear multiple therapeutic agents in one system. The purpose of this study is to deliver human tumor necrosis factor (TNF) -related apoptosis-inducing ligand (Apo2L/TRAIL) and doxorubicin (Dox, an anti-cancer drug) with micellar nanoparticles self-assembled from a biodegradable cationic copolymer P(MDS-co-CES) to achieve synergistic cytotoxic effects in cancer cells. Effects of nanocomplexes on both wild type and TRAIL-resistant SW480 colorectal carcinoma cells were investigated. Cytotoxicity of the nanocomplexes to non-cancerous cells was significantly lower than cancerous cells. Anti-proliferative effects of nanocomplexes were retained in remaining cancer cells in long-term cultures after treatment with the nanocomplexes. In summary, this Dox and TRAIL co-delivery system can be a promising candidate for cancer treatment.
first_indexed 2025-11-14T09:55:08Z
format Conference Paper
id curtin-20.500.11937-53417
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:55:08Z
publishDate 2012
publisher American Chemical Society
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-534172017-10-10T03:37:24Z Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles Lee, A. Dhillon, S. Wang, Y. Pervaiz, Shazib Yang, Y. The use of small molecule drugs in cancer chemotherapy has mostly been limited by dose-dependent toxicity and development of drug resistance resulting from repeated administrations. To overcome such problems, efforts have been made to develop drug delivery systems that can bear multiple therapeutic agents in one system. The purpose of this study is to deliver human tumor necrosis factor (TNF) -related apoptosis-inducing ligand (Apo2L/TRAIL) and doxorubicin (Dox, an anti-cancer drug) with micellar nanoparticles self-assembled from a biodegradable cationic copolymer P(MDS-co-CES) to achieve synergistic cytotoxic effects in cancer cells. Effects of nanocomplexes on both wild type and TRAIL-resistant SW480 colorectal carcinoma cells were investigated. Cytotoxicity of the nanocomplexes to non-cancerous cells was significantly lower than cancerous cells. Anti-proliferative effects of nanocomplexes were retained in remaining cancer cells in long-term cultures after treatment with the nanocomplexes. In summary, this Dox and TRAIL co-delivery system can be a promising candidate for cancer treatment. 2012 Conference Paper http://hdl.handle.net/20.500.11937/53417 https://www.acs.org/content/acs/en/meetings/nationalmeetings/programarchive.html American Chemical Society restricted
spellingShingle Lee, A.
Dhillon, S.
Wang, Y.
Pervaiz, Shazib
Yang, Y.
Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title_full Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title_fullStr Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title_full_unstemmed Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title_short Synergistic anticancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL) and doxorubicin using micellar polymer nanoparticles
title_sort synergistic anticancer effects via co-delivery of tnf-related apoptosis-inducing ligand (trail) and doxorubicin using micellar polymer nanoparticles
url https://www.acs.org/content/acs/en/meetings/nationalmeetings/programarchive.html
http://hdl.handle.net/20.500.11937/53417